Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The latest revision recognizes the importance of treatment as prevention.
Around 38,000 new HIV cases still occur each year, and more than 80% of people who could benefit from PrEP aren’t using it.
Long-acting injectables may be given once every other month, according to new findings.
The Miami program IDEA Exchange provides secure locations to store meds.
Surveys reveal difficulties associated with daily pills and a desire for long-acting injectable therapy.
Over $12 million in grants has been awarded to the Wistar Institute to research the links between opioid receptors and immune activation.
A high proportion of people with HIV suffer from anxiety, which is associated with lower rates of HIV treatment and adherence to treatment.
Merck’s experimental HIV drug proves effective and well tolerated
The investigational, injectable, long-acting antiretroviral is a potential new option for those with multidrug resistance.
The attachment inhibitor plus an optimized antiretroviral background regimen suppressed HIV in the majority of study participants.
A new analysis of the global START trial found that health outcomes were better for those starting treatment within six months.
These medications can now be used by people on stable antiretroviral treatment with undetectable viral load.
Class action lawsuit challenges deals that limit generic drug competition; Gilead says the case is without merit.
Some groups, however, including Black and Latino men and homeless people, are not faring as well as others.
The newer tenofovir formulation can raise cholesterol and triglyceride levels, but these changes are reversible.
The increasing mastery over the virus is one of humanity’s crowning achievements.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.